Fluoroquinolone derivatives in the treatment of mycobacterium tuberculosis infection

João Pedro Pais, Margarida Policarpo, David Pires, Ana Paula Francisco, Ana Margarida Madureira, Bernard Testa, Elsa Anes, Luis Constantino*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Tuberculosis (TB) is currently one of the leading causes of death due to infective agents, and the growing rate of multidrug-resistant tuberculosis (MDR TB) cases poses an emergent public health threat. Fluoroquinolones are commonly used in the treatment of both MDR TB and drug-sensitive tuberculosis patients who are intolerant to first-line antitubercular agents. Unfortunately, these drugs have mild side effects, relevant to the prolonged treatment regimens and diminished bioavailability due to binding of metal ions. Moreover, the resistance to fluoroquinolones is also on the rise, a characteristic of extensively drug-resistant TB (XDR TB). Here, we developed esters as prodrugs of the fluoroquinolones levofloxacin and ciprofloxacin, with long-chain fatty alcohols. Both the alcohols and the quinolone have previously shown antimycobacterial activity and the aim was to develop esters with improved lipophilicity and capable of delivering the free acid inside mycobacterial cells. The carboxylic acid group of fluoroquinolones is essential to the mode of action but is also responsible for many of its side effects and metal-chelating properties. The synthesis, stability in biological media, and antibacterial activity were evaluated, the latter not only against Mycobacterium tuberculosis but also against other clinically relevant bacterial species, since the parent compounds display a broad spectrum of activity. The biological results show a reduction in the antitubercular activity of the synthesized derivatives, probably due to deficient activation of the ester prodrug. Despite this, it was found that the derivatives exhibit bioactivity against other fluoroquinolone-resistant bacteria, indicating a different mode of action and suggesting that it may be worthwhile to research further modifications to the carboxylic acid group. This might lead to new compounds that are efficient against resistant strains. This idea that the compounds may act by a different mechanism of action was further supported by a brief computer investigation that demonstrated the potential lack of selectivity of the esters to the fluoroquinolone target.
Original languageEnglish
Article number1213
Number of pages13
JournalPharmaceuticals
Volume15
Issue number10
DOIs
Publication statusPublished - Oct 2022
Externally publishedYes

Keywords

  • esters
  • fluoroquinolones
  • mycobacteria
  • prodrugs
  • tuberculosis

Fingerprint

Dive into the research topics of 'Fluoroquinolone derivatives in the treatment of mycobacterium tuberculosis infection'. Together they form a unique fingerprint.

Cite this